A share price of Dianthus Therapeutics Inc [DNTH] is currently trading at $44.1, up 0.23%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The DNTH shares have gain 15.48% over the last week, with a monthly amount glided 6.52%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Dianthus Therapeutics Inc [NASDAQ: DNTH] stock has seen the most recent analyst activity on October 14, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $56. On December 20, 2024, TD Cowen initiated with a Buy rating. Oppenheimer started tracking the stock assigning an Outperform rating and suggested a price target of $48 on October 03, 2024. Robert W. Baird initiated its recommendation with an Outperform and recommended $58 as its price target on July 26, 2024. In a note dated May 16, 2024, H.C. Wainwright initiated a Buy rating and provided a target price of $40 on this stock.
Dianthus Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $13.36 and $46.59. Currently, Wall Street analysts expect the stock to reach $69 within the next 12 months. Dianthus Therapeutics Inc [NASDAQ: DNTH] shares were valued at $44.1 at the most recent close of the market. An investor can expect a potential return of 56.46% based on the average DNTH price forecast.
Analyzing the DNTH fundamentals
Trailing Twelve Months sales for Dianthus Therapeutics Inc [NASDAQ:DNTH] were 3.08M which represents -81.77% decline. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -45.58%, Pretax Profit Margin comes in at -41.05%, and Net Profit Margin reading is -41.05%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.33 and Total Capital is -0.25. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Dianthus Therapeutics Inc [NASDAQ:DNTH] is 17.35. In addition, the Quick Ratio stands at 17.35 and the Cash Ratio stands at 2.35. Considering the valuation of this stock, the price to sales ratio is 613.91, the price to book ratio is 3.46.
Transactions by insiders
Recent insider trading involved Savitz Ryan, CFO & CBO, that happened on Dec 04 ’25 when 20000.0 shares were sold. Officer, RYAN SAVITZ completed a deal on Dec 04 ’25 to buy 20000.0 shares. Meanwhile, EVP, Head of R&D Randhawa Simrat sold 0.11 million shares on Nov 14 ’25.
